Donepezil, rivastigmine, galantamine and memantine for ...

Ongoing research, with relevance to the
assessment of donepezil, rivastigmine,
galantamine or memantine for AD, is described
below.
The EXCEED study is a prospective, 24-month,
multicentre, multinational, randomised, doubleblind,
parallel group study comparing treatment
with rivastigmine with treatment with donepezil.
Participants in the trial are classed as moderate to
moderately severe AD (MMSE score of 10–20)
aged 50–85 years. Outcome measures include the
SIB, the GDS, ADCS/ADL, NPI, NPI-D and
MMSE and use of concomitant psychotropic
medications. The EXCEED study is funded by
Novartis (manufacturers of rivastigmine) and at
the time of writing is expected to complete in late
2004.
Chapter 7
Research in progress
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 1
A pilot study comparing the effect of galantamine
with donepezil in patients with moderate or severe
AD is currently ongoing. This is a multicentre,
randomised, rater-blinded study. Outcomes
include the effect on behavioural symptoms,
cognition, ADLs and resource utilisation. This
study is funded by Shire (manufacturers of
galantamine). The expected completion date was
not available.
The ‘Memantine once daily dosing and simplified
dose titration study’ is a multicentre, double-blind
randomised controlled trial of patients with
moderately severe to severe AD. Outcomes include
safety, vital signs and the CGIC scale. This study is
funded by Lundbeck (manufacturers of memantine)
and at the time of writing is expected to complete
in late 2004.
139